Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	17133
Country	France

Received	2015-02-21 10:55
Peer-Review Started	2015-02-22 11:31
To Make the First Decision	2015-03-20 14:33
Return for Revision	2015-03-20 21:36
Revised	2015-04-07 00:14
Second Decision	2015-05-15 17:27
Accepted by Journal Editor-in-Chief	2015-05-16 02:33
Accepted by Company Editor-in-Chief	2015-05-28 18:12
Articles in Press	2015-05-28 18:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-29 17:00
Publish the Manuscript Online	2015-08-14 18:36

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Anti program death-1/anti program death-ligand 1 in digestive cancers
Manuscript Source	Invited Manuscript
All Author List	Eléonore de Guillebon, Pauline Roussille, Eric Frouin and David Tougeron
Funding Agency and Grant Number
Corresponding Author	David Tougeron, MD, PhD, Gastroenterology Department, Poitiers University Hospital, 2 rue de la Milétrie, 86000 Poitiers, France. david.tougeron@chu-poitiers.fr
Key Words	Program death-1; Program death-ligand 1; Antibody; Digestive cancer
Core Tip	Anti-program death-1 and anti-program death-ligand 1 (PD-L1) monoclonal antibodies have been designed to restore T cell activity, since human tumors tend to activate this immune regulatory checkpoint as a means of escaping immunosurveillance. A PD-L1 expression is present in 30% to 50% of digestive cancers and accumulating data are in favor of an association between this PD-L1 expression and response to treatment, which make digestive cancers promising candidates for those breakthrough immunotherapies. We review the ongoing clinical trials and the major challenges ahead of us in order to learn how, when and for which patients we should use these therapeutics.
Publish Date	2015-08-14 18:36
Citation	de Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101
URL	http://www.wjgnet.com/1948-5204/full/v7/i8/95.htm
DOI	http://dx.doi.org/10.4251/wjgo.v7.i8.95

Full Article (PDF)	WJGO-7-95.pdf
Full Article (Word)	WJGO-7-95.doc
Manuscript File	17133-Review.doc
Answering Reviewers	17133-Answering reviewers.pdf
Audio Core Tip	17133-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17133-Conflict-of-interest statement.pdf
Copyright License Agreement	17133-Copyright assignment.pdf
Peer-review Report	17133-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	17133-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17133-Scientific misconduct check.pdf
Scientific Editor Work List	17133-Scientific editor work list.pdf